Glaukos (NYSE:GKOS) Given New $240.00 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan raised Glaukos’s price target to $240 from $200 and maintained an “overweight” rating. Piper Sandler also set a $240 target, while the analyst consensus is a “Moderate Buy” with a $216.71 target.
• Glaukos reported strong quarterly results, with revenue up 58% year over year to $211 million and adjusted EPS of $0.47 versus analyst expectations for a loss. The company also raised its 2026 sales forecast to $775 million–$785 million and introduced a preliminary $1 billion sales goal for 2027.
• Shares surged to $240.81, near their 52-week high, following the results and target increases. However, the company still has negative GAAP profitability measures, and insiders have sold shares without reported purchases over the past six months.

Glaukos (NYSE:GKOS - Get Free Report) had its price target boosted by stock analysts at JPMorgan Chase & Co. from $200.00 to $240.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the medical instruments supplier's stock. JPMorgan Chase & Co.'s price objective suggests a potential downside of 0.34% from the company's previous close.

A number of other equities research analysts have also issued reports on the company. Piper Sandler reaffirmed an "overweight" rating and issued a $240.00 target price (up from $195.00) on shares of Glaukos in a research note on Thursday. Jefferies Financial Group increased their target price on Glaukos from $190.00 to $210.00 and gave the company a "buy" rating in a report on Tuesday, September 22nd. Stifel Nicolaus raised their price target on Glaukos from $190.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday. HC Wainwright reissued a "buy" rating and issued a $248.00 price target on shares of Glaukos in a report on Thursday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Glaukos in a research note on Thursday, October 15th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $216.71.

Glaukos Price Performance

GKOS traded up $59.38 on Thursday, hitting $240.81. 5,410,393 shares of the company were exchanged, compared to its average volume of 901,912. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The business's fifty day moving average is $171.24 and its 200 day moving average is $139.87. Glaukos has a fifty-two week low of $80.90 and a fifty-two week high of $243.71. The firm has a market capitalization of $14.20 billion, a P/E ratio of -74.10 and a beta of 0.69.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.57. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company had revenue of $211.03 million during the quarter, compared to the consensus estimate of $168.04 million. During the same period last year, the firm earned ($0.16) EPS. The company's revenue for the quarter was up 58.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Glaukos will post -0.32 EPS for the current year.

Insiders Place Their Bets

In related news, Director Leana Wen sold 525 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $167.63, for a total transaction of $88,005.75. Following the transaction, the director directly owned 21,092 shares in the company, valued at approximately $3,535,651.96. This represents a 2.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Gilbert Kliman sold 2,500 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director owned 37,406 shares in the company, valued at $7,107,140. This trade represents a 6.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 83,025 shares of company stock valued at $14,950,006. 5.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. State of Wyoming boosted its position in Glaukos by 6.8% during the 3rd quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier's stock worth $169,000 after acquiring an additional 66 shares during the period. Wealth Alliance LLC raised its position in shares of Glaukos by 4.5% during the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier's stock worth $247,000 after purchasing an additional 98 shares during the period. Abel Hall LLC raised its holdings in Glaukos by 3.5% during the 3rd quarter. Abel Hall LLC now owns 3,236 shares of the medical instruments supplier's stock worth $531,000 after buying an additional 108 shares during the period. Choreo LLC lifted its position in shares of Glaukos by 4.0% in the 3rd quarter. Choreo LLC now owns 3,546 shares of the medical instruments supplier's stock valued at $582,000 after acquiring an additional 136 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Glaukos by 25.4% in the third quarter. Farther Finance Advisors LLC now owns 681 shares of the medical instruments supplier's stock worth $112,000 after buying an additional 138 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Third-quarter revenue rose 58% year over year to $211.0 million, substantially exceeding the roughly $168 million analyst estimate. Adjusted EPS of $0.47 also surpassed consensus expectations for a loss, while reported net income reached $2.0 million, or $0.03 per diluted share, compared with a loss a year earlier. Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
• Positive Sentiment: Glaukos raised its 2026 sales forecast to $775 million-$785 million from $680 million-$700 million and introduced a preliminary 2027 sales goal of $1 billion. The target suggests management expects continued rapid adoption across its glaucoma and corneal-health franchises. Glaukos Corporation Provides Sales Guidance for 2027
• Positive Sentiment: Analysts lifted their price targets following the earnings report: Needham raised its target to $251 and maintained a buy rating, while BTIG and Stifel raised targets to $234 and $225, respectively. Wells Fargo increased its target to $226 and assigned an overweight rating. Needham analyst rating
• Neutral Sentiment: The quarter generated $14.8 million in operating cash flow, and Glaukos ended it with $162.3 million in cash and cash equivalents. These figures provide financial flexibility, although the company remains loss-making on some profitability measures.
• Negative Sentiment: Profitability was less robust under GAAP than the adjusted EPS headline indicates: operating profit was only $0.8 million, and the company continues to report a negative net margin. In addition, the referenced insider-trading data shows 32 open-market sales and no purchases over the past six months, which may temper enthusiasm at the elevated valuation.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company's principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.